NDT Advance Access originally published online on July 19, 2005
Nephrology Dialysis Transplantation 2005 20(10):2259-2261; doi:10.1093/ndt/gfh975
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Case Report
Massive bowel infarction after percutaneous transluminal renal angioplasty
Nephrology and Dialysis Department, Silvestrini Hospital, Perugia, Italy
Correspondence and offprint requests to: Riccardo Maria Fagugli, MD, S.C. Nefrologia e Dialisi, Ospedale Silvestrini, Azienda Ospedaliera di Perugia, San Andrea delle Fratte, 06100 Perugia, Italy. Email: rmfag@tin.it
Keywords: atherosclerotic renal artery stenosis; cholesterol crystal embolization; percutaneous transluminal renal angioplasty
| The first 10% of the full text of this article appears below. |
| Introduction |
|---|
We report the case of a patient with atherosclerotic renal artery stenosis (ARAS) who developed massive bowel infarction caused by cholesterol crystal embolization (CCE) after percutaneous transluminal renal angioplasty (PTRA).
CCE is a complication of diffuse atherosclerosis, and it is responsible for a variety of complex clinical findings due to various degrees of multi-organ damage; it can range from being clinically silent to resembling other systemic diseases, such as vasculitis [1]. CCE in the vessels of the digestive tract suggests a very advanced and diffuse atherosclerosis with a serious outcome. Although CCE is a recognized complication of intra-arterial catheter manipulation, bowel infarction due to CCE after percutaneous treatment of ARAS is rare. Considering that the best treatment of atheroembolic disease is prevention, clinicians should be aware of this condition, especially in view of the increasing size of the population with atherosclerosis that
| Case |
|---|
| Discussion |
|---|